Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
9.98
+0.16 (1.63%)
Jun 10, 2026, 3:01 PM EDT - Market open
Phathom Pharmaceuticals Revenue
Phathom Pharmaceuticals had revenue of $58.30M in the quarter ending March 31, 2026, with 104.43% growth. This brings the company's revenue in the last twelve months to $204.89M, up 150.30% year-over-year. In the year 2025, Phathom Pharmaceuticals had annual revenue of $175.11M with 216.93% growth.
Revenue (ttm)
$204.89M
Revenue Growth
+150.30%
P/S Ratio
3.81
Revenue / Employee
$552,270
Employees
371
Market Cap
792.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 175.11M | 119.86M | 216.93% |
| Dec 31, 2024 | 55.25M | 54.57M | 8,001.47% |
| Dec 31, 2023 | 682.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zevra Therapeutics | 122.29M |
| Kura Oncology | 71.64M |
| Evommune | 10.00M |
| Inventiva | 7.94M |
| Odyssey Therapeutics | 2.98M |
PHAT News
- 1 day ago - Phathom Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 7 days ago - Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 15 days ago - Needham pharmaceuticals analysts hold analyst/industry conference call - TheFly
- 19 days ago - Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 21 days ago - Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting - GlobeNewsWire
- 5 weeks ago - Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting - GlobeNewsWire
- 5 weeks ago - Phathom Pharmaceuticals reports Q1 non-GAAP EPS (18c), consensus (19c) - TheFly
- 5 weeks ago - Phathom Pharmaceuticals still sees 2026 revenue $320M-$34M, consensus $332.04M - TheFly